Nanobiotix (NASDAQ:NBTX) Sees Unusually-High Trading Volume – Should You Buy?

Nanobiotix S.A. Sponsored ADR (NASDAQ:NBTX) shares saw an uptick in trading volume on Monday . 49,322 shares were traded during mid-day trading, an increase of 173% from the previous session’s volume of 18,042 shares.The stock last traded at $16.82 and had previously closed at $16.24.

Analyst Ratings Changes

A number of brokerages have commented on NBTX. HC Wainwright reaffirmed a “buy” rating on shares of Nanobiotix in a report on Friday, September 19th. Leerink Partners set a $14.00 target price on Nanobiotix in a report on Thursday, September 18th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, Nanobiotix currently has a consensus rating of “Moderate Buy” and an average target price of $11.00.

Nanobiotix Trading Up 12.9%

The firm has a fifty day moving average price of $8.94 and a 200-day moving average price of $5.74.

Institutional Trading of Nanobiotix

An institutional investor recently bought a new position in Nanobiotix stock. Jane Street Group LLC acquired a new stake in Nanobiotix S.A. Sponsored ADR (NASDAQ:NBTX) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 23,283 shares of the company’s stock, valued at approximately $73,000. Institutional investors own 38.81% of the company’s stock.

Nanobiotix Company Profile

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.